Man Group
CPRX

Man Group’s Catalyst Pharmaceutical CPRX Stock Holding History

Man Group’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.13M Sell
85,838
-102,946
-55% -$2.45M ﹤0.01% 1552
2025
Q4 		$4.41M Sell
188,784
-275,218
-59% -$6.13M 0.01% 1139
2025
Q3 		$9.14M Buy
464,002
+33,098
+8% +$681K 0.02% 838
2025
Q2 		$9.35M Buy
430,904
+135,162
+46% +$3.19M 0.02% 805
2025
Q1 		$7.17M Sell
295,742
-20,075
-6% -$452K 0.02% 862
2024
Q4 		$6.59M Buy
315,817
+61,123
+24% +$1.31M 0.02% 907
2024
Q3 		$5.06M Sell
254,694
-215,150
-46% -$3.99M 0.01% 1022
2024
Q2 		$7.28M Sell
469,844
-149,567
-24% -$2.33M 0.02% 844
2024
Q1 		$9.87M Sell
619,411
-24,805
-4% -$374K 0.02% 705
2023
Q4 		$10.8M Buy
+644,216
New +$8.81M 0.03% 602
2023
Q3 		– Sell
-835,008
Closed -$11.2M – 711
2023
Q2 		$11.2M Buy
+835,008
New +$12M 0.03% 584
2023
Q1 		– Sell
-889,532
Closed -$14.7M – 428
2022
Q4 		$16.5M Buy
889,532
+102,432
+13% +$1.58M 0.06% 398
2022
Q3 		$10.1M Buy
+787,100
New +$9.33M 0.05% 471
2022
Q2 		– Sell
-256,100
Closed -$1.88M – 1115
2022
Q1 		$2.12M Sell
256,100
-136,800
-35% -$967K 0.01% 1203
2021
Q4 		$2.66M Buy
392,900
+87,000
+28% +$572K 0.01% 1094
2021
Q3 		$1.62M Hold
305,900
– – 0.01% 1225
2021
Q2 		$1.76M Sell
305,900
-58,327
-16% -$301K 0.01% 1258
2021
Q1 		$1.68M Sell
364,227
-629,335
-63% -$2.5M 0.01% 1162
2020
Q4 		$3.32M Sell
993,562
-141,500
-12% -$475K 0.01% 994
2020
Q3 		$3.37M Buy
1,135,062
+85,327
+8% +$334K 0.01% 1003
2020
Q2 		$4.85M Buy
1,049,735
+941,435
+869% +$4.23M 0.02% 678
2020
Q1 		$417K Buy
108,300
+34,500
+47% +$142K ﹤0.01% 1322
2019
Q4 		$277K Buy
+73,800
New +$345K ﹤0.01% 1689

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Man Group's CPRX Position: Q1 2026 in Review

Man Group reduced its Catalyst Pharmaceutical (CPRX) stake by 55% in Q1 2026, selling an estimated $2.45M and leaving 85,838 shares worth $2.13M. The position accounts for ﹤0.01% of the portfolio, ranked #1552.

Man Group first reported a position in CPRX in Q4 2019 and has held it in 23 quarters since. The position peaked at $16.5M in Q4 2022. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Man Group held 85,838 shares of Catalyst Pharmaceutical worth $2.13M as of Q1 2026.
  • Man Group sold 102,946 Catalyst Pharmaceutical shares in Q1 2026, an estimated $2.45M.
  • Catalyst Pharmaceutical made up ﹤0.01% of Man Group's portfolio in Q1 2026, its #1552 holding.
  • Man Group first reported a position in Catalyst Pharmaceutical in Q4 2019 and has held it in 23 quarters since.
  • Man Group's Catalyst Pharmaceutical position peaked at $16.5M in Q4 2022.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Man Group's 13F filing for Q1 2026, filed 15 May 2026.